Breaking News, Collaborations & Alliances

MyoKardia Regains Global Rights to Programs from Sanofi

License agreement with Sanofi for lead clinical-stage candidates, mavacamten and MYK-491, ended on December 31, 2018

MyoKardia has regained worldwide rights to all programs covered under its license and collaboration agreement with Sanofi. The collaboration will not be extended beyond the initial research term, which ended on December 31, 2018, and will conclude in its entirety effective April 1, 2019. As a result, MyoKardia now has global rights to all programs in its portfolio, including lead clinical-stage candidates, mavacamten and MYK-491. “We are grateful for Sanofi’s support over the past four ye...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters